N6AMT1 Antibody

What is N6AMT1 and what are its primary functions?

N6AMT1 is a nucleo-cytosolic methyltransferase that exhibits genetic co-dependency with mitochondria. Despite not being localized within mitochondria, N6AMT1 is essential for mitochondrial gene expression and function . It functions as a protein methyltransferase when complexed with the co-factor TRMT112 . N6AMT1 is suggested to be involved in regulating vital cellular processes including cell cycle, proliferation, division, and apoptotic processes . Recent research has demonstrated its critical role in cytosolic synthesis of key subunits of the mitochondrial RNA processing machinery . Genetic ablation of N6amt1 in mice is lethal, highlighting its essential functions .

Which commercially available N6AMT1 antibodies are most widely used in research?

Current research indicates that at least 22 different N6AMT1 antibodies are commercially available . Among these, six have been specifically analyzed for their research applications: HPA059242 (Atlas Antibodies), CQA1550 (Cohesion Biosciences), 16211-1-AP (Proteintech), ARP45845_P050 (Aviva Systems Biology), PA5-121076 (Invitrogen), and sc-517120 (Santa Cruz Biotechnology) . These antibodies vary in type (five are rabbit polyclonal and one is mouse monoclonal) and were raised against different N6AMT1 immunogens ranging from small synthetic peptides to full-length recombinant proteins . The most cited antibody in literature appears to be an in-house generated antibody (#27630) that is not commercially available .

What cellular localization pattern does N6AMT1 exhibit?

N6AMT1 exhibits a nucleo-cytosolic localization pattern without colocalization with mitochondria, as confirmed through confocal microscopy across multiple cell lines . This is particularly interesting given its critical role in mitochondrial function despite not being present within mitochondria . The subcellular localization has been documented in databases including UniProt and HPA (Human Protein Atlas) . This localization pattern is important to consider when designing experiments to study N6AMT1 function and when interpreting immunofluorescence results.

How should researchers address the cross-reactivity issue of N6AMT1 antibodies with Aurora Kinase A?

Recent studies have identified that three commercial polyclonal antibodies raised against N6AMT1 strongly cross-react with endogenous and recombinant Aurora kinase A (AURKA) . This cross-reactivity was verified through multiple techniques including immunofluorescence, immunoblot, and immunoprecipitation assays combined with mass spectrometry .

To address this issue, researchers should:

• Include appropriate controls: Always include N6AMT1 knockdown/knockout controls when validating antibody specificity.

• Employ multiple detection methods: Combine immunoblotting with immunoprecipitation followed by mass spectrometry to confirm protein identity.

• Examine shared epitopes: Be aware that N6AMT1 and AURKA share the protein motif ENNPEE, which is unique to only these two proteins and is likely the cause of cross-reactivity .

• Consider alternative antibodies: Of the six analyzed antibodies, not all showed cross-reactivity. Two failed to recognize endogenous or recombinant N6AMT1, one recognized both but had strong background, and three polyclonal antibodies showed strong cross-reactivity with AURKA .

• Implement orthogonal validation: Use genetic approaches (siRNA, CRISPR) to validate findings obtained with antibodies.

What methodological approaches should be used to study N6AMT1's role in mitochondrial function?

Despite being a nucleo-cytosolic protein, N6AMT1 plays a critical role in mitochondrial function. To study this relationship, researchers should employ the following methodological approaches:

• Genetic dependency analysis: Analyze genetic dependency profiles across cancer cell lines to identify correlations between N6AMT1 and mitochondrial genes. This approach revealed that N6AMT1 correlates best with nuclear-encoded genes coding for mitochondrial proteins (MitoCarta3.0 genes) .

• RNA sequencing with mitochondrial focus: Include mitochondrial genome-encoded genes in RNA-Seq analysis. This revealed decreased levels of all 13 mt-mRNAs in N6AMT1-depleted cells .

• Respiration measurements: Assess mitochondrial function through respiration assays. N6AMT1-depleted cells showed decreased respiration .

• Mitochondrial RNA processing analysis: Investigate mt-RNA processing since N6AMT1 is required for the cytosolic synthesis of key subunits of the mitochondrial RNA processing machinery .

• Interferon response assessment: Measure interferon response markers, as depletion or catalytic inactivation of N6AMT1 results in accumulation of unprocessed and double-stranded mt-RNA, leading to an interferon response .

How can researchers differentiate between N6AMT1's DNA methylation and protein methylation functions experimentally?

There is ongoing debate and conflicting results regarding N6AMT1's role in DNA methylation, specifically 6mA modification . To differentiate between its DNA and protein methylation functions:

• Methyltransferase activity assays: Conduct in vitro methyltransferase assays using purified N6AMT1-TRMT112 complex with different substrates (DNA vs. proteins) and analyze transfer of methyl groups using radiolabeled SAM (S-adenosylmethionine).

• Mutation analysis: Generate catalytic-dead mutants of N6AMT1 and assess their impact on both DNA and protein methylation patterns.

• Mass spectrometry analysis: Use quantitative mass spectrometry to identify methylated residues on target proteins and correlate with N6AMT1 expression/activity.

• Genomic approaches: Employ techniques such as 6mA-IP-seq, SMRT-seq, or 6mA-RE-seq to map 6mA sites in DNA genome-wide and correlate with N6AMT1 expression.

• Structural studies: Investigate binding preferences of N6AMT1 for DNA versus protein substrates through crystallography or cryo-EM studies.

What approaches should be used to investigate N6AMT1 as a cancer biomarker?

N6AMT1 has emerged as a potential diagnostic, prognostic, and immunotherapy response biomarker in cancer . To investigate its biomarker potential:

• Pan-cancer expression analysis: Analyze N6AMT1 expression across different cancer types using databases like TCGA to identify cancer-specific patterns .

• Survival analysis: Correlate N6AMT1 expression with patient survival data to assess prognostic value .

• Immunotherapy response correlation: Analyze datasets from immunotherapy trials (e.g., GSE168204, GSE67501, IMvigor210) to correlate N6AMT1 expression with treatment response .

• Tumor microenvironment analysis: Use computational methods like CIBERSORT and ESTIMATE to explore correlations between N6AMT1 expression and tumor immune microenvironment characteristics .

• Multivariate analysis: Combine N6AMT1 expression data with other clinical parameters to develop integrated prognostic or predictive models.

• Functional validation: Perform mechanistic studies in cancer models to understand how N6AMT1 influences cancer development and progression.

What controls are essential when using N6AMT1 antibodies for Western blot or immunoprecipitation?

When using N6AMT1 antibodies for Western blot or immunoprecipitation, the following controls are essential:

• Positive controls: Include recombinant N6AMT1 protein or cell lines known to express high levels of N6AMT1.

• Negative controls: Include N6AMT1 knockout or knockdown samples to confirm specificity of the detected band.

• Aurora Kinase A controls: Given the documented cross-reactivity with AURKA, include samples with varying AURKA expression to distinguish signals .

• Loading controls: Use appropriate housekeeping proteins (e.g., GAPDH) for normalization in Western blots .

• IgG controls: For immunoprecipitation, include IgG controls from the same species as the N6AMT1 antibody.

• Cell cycle-synchronized samples: Since AURKA expression peaks during G2/M phase, consider using synchronized cells to differentiate between N6AMT1 and AURKA signals .

• Multiple antibodies: Use at least two different N6AMT1 antibodies targeting different epitopes to confirm findings.

How should researchers integrate N6AMT1 study with mitochondrial research techniques?

To effectively integrate N6AMT1 study with mitochondrial research:

• Combined analysis approaches: Integrate cytosolic and mitochondrial fractionation studies with N6AMT1 functional analysis.

• Mitochondrial RNA processing assessment: Focus on the RNA processing machinery components that depend on N6AMT1 for their translation .

• Respiratory chain analysis: Measure individual respiratory chain complex activities to pinpoint where mitochondrial function is compromised in N6AMT1-deficient cells .

• Mitochondrial translation experiments: Perform mitochondrial translation assays (e.g., 35S-methionine pulse labeling) to directly measure the impact of N6AMT1 on mitochondrial protein synthesis .

• Double-stranded RNA detection: Implement techniques to detect double-stranded mitochondrial RNA accumulation, which occurs upon N6AMT1 depletion and may trigger interferon responses .

• Coordinated expression analysis: Design experiments to investigate the coordinated expression of nuclear and mitochondrial genomes and how N6AMT1 influences this coordination .

How can researchers reconcile conflicting reports about N6AMT1's role in DNA methylation?

There is ongoing debate about N6AMT1's role in DNA methylation, particularly regarding 6mA modification . To reconcile conflicting reports:

• Systematic technique comparison: Compare methodologies used in conflicting studies, focusing on detection methods, cell types, and experimental conditions.

• Context-dependent function analysis: Investigate whether N6AMT1's DNA methylation activity is context-dependent (e.g., cell type-specific, stress-induced).

• Quantitative assessment: Implement quantitative methods like mass spectrometry to measure absolute levels of 6mA under different conditions.

• Genetic complementation experiments: Conduct rescue experiments with wild-type vs. catalytic mutants of N6AMT1 to determine if DNA methylation activity is required for specific functions.

• Temporal analysis: Consider whether N6AMT1's function in DNA methylation may be temporally regulated (e.g., cell cycle-dependent, development-specific).

• Multi-omics integration: Integrate methylome, transcriptome, and proteome data to build a comprehensive understanding of N6AMT1 function.

What strategies should be employed to distinguish genuine N6AMT1 signals from Aurora Kinase A cross-reactivity in immunoassays?

To distinguish genuine N6AMT1 signals from Aurora Kinase A cross-reactivity:

• Compare band patterns: N6AMT1 (25 kDa) and AURKA (48 kDa) have different molecular weights, so compare band patterns with predicted sizes .

• Use genetic controls: Implement N6AMT1 and AURKA knockdown/knockout controls to identify specific signals.

• Differential expression analysis: Exploit conditions where expression of one protein changes while the other remains constant.

• Block with competing peptides: Use peptides containing the shared ENNPEE motif to block cross-reactivity .

• Immunodepletion experiments: Sequentially deplete samples of AURKA and then probe for N6AMT1, or vice versa.

• Cell cycle analysis: Since AURKA expression peaks during G2/M phase, compare samples from different cell cycle stages .

• Confirming identity by mass spectrometry: Following immunoprecipitation, confirm protein identity through mass spectrometry analysis .

What are the emerging roles of N6AMT1 in coordinating nuclear and mitochondrial genome expression?

Recent research has revealed that N6AMT1 plays a crucial role in coordinating nuclear and mitochondrial genome expression through several mechanisms:

• Mitochondrial RNA processing regulation: N6AMT1 is required for the cytosolic synthesis of key subunits of the mitochondrial RNA processing machinery .

• Prevention of double-stranded RNA accumulation: N6AMT1 depletion results in accumulation of unprocessed and double-stranded mitochondrial RNA, suggesting a role in maintaining mitochondrial RNA homeostasis .

• Interferon response modulation: The accumulation of double-stranded mitochondrial RNA in N6AMT1-deficient cells triggers an interferon response, linking mitochondrial function to innate immunity .

• Mitochondrial translation support: Despite being a cytosolic protein, N6AMT1 supports mitochondrial protein synthesis, suggesting a role in coordinating cytosolic and mitochondrial translation programs .

• Potential role in mitochondrial-nuclear communication: The genetic co-dependency between N6AMT1 and mitochondrial genes suggests its involvement in retrograde signaling pathways that communicate mitochondrial status to the nucleus .

How does N6AMT1 contribute to cancer development and potential therapeutic targeting?

N6AMT1's contribution to cancer development and its potential as a therapeutic target involves several aspects:

• Differential expression in cancers: N6AMT1 shows altered expression across various cancer types, suggesting a role in tumorigenesis .

• Prognostic value: Studies have identified N6AMT1 as a prognostic biomarker in various cancers .

• Immunotherapy response prediction: N6AMT1 expression correlates with immunotherapy response, making it a potential predictive biomarker for immunotherapy efficacy .

• Tumor immune microenvironment modulation: N6AMT1 expression correlates with changes in the tumor immune microenvironment, potentially affecting anti-tumor immunity .

• Mitochondrial function in cancer: Given N6AMT1's role in mitochondrial function, it may contribute to metabolic reprogramming in cancer cells .

• Cell proliferation and apoptosis regulation: N6AMT1 is involved in regulating cell cycle, proliferation, and apoptotic processes, all of which are dysregulated in cancer .

• Potential druggable target: As a methyltransferase, N6AMT1 represents a potentially druggable target for cancer therapy, similar to other epigenetic enzymes.

What strategies should be employed when N6AMT1 antibody yields inconsistent results across different experimental applications?

When encountering inconsistent results with N6AMT1 antibodies:

• Validate with multiple antibodies: Use multiple antibodies targeting different epitopes of N6AMT1 to confirm results.

• Optimize fixation and permeabilization: For immunofluorescence, test different fixation methods (paraformaldehyde, methanol, acetone) and permeabilization reagents.

• Adjust blocking conditions: Test different blocking agents (BSA, normal serum, commercial blockers) to reduce non-specific binding.

• Implement epitope retrieval: For tissues or challenging samples, try antigen retrieval methods to improve epitope accessibility.

• Consider sample preparation variables: Cell cycle stage, confluence, and stress conditions can affect N6AMT1 expression and localization.

• Account for cross-reactivity: Be aware of the documented cross-reactivity with AURKA and design experiments accordingly .

• Validate with genetic approaches: Confirm antibody specificity using N6AMT1 knockdown/knockout controls.

• Check for post-translational modifications: Consider whether post-translational modifications might affect antibody recognition.

How can researchers accurately quantify changes in N6AMT1 expression levels given the antibody specificity challenges?

To accurately quantify N6AMT1 expression despite antibody specificity challenges:

• mRNA quantification: Use RT-qPCR to measure N6AMT1 mRNA levels as a complementary approach to protein detection.

• Mass spectrometry-based proteomics: Implement targeted proteomics approaches to quantify N6AMT1 protein levels using unique peptides.

• Tagged expression systems: For exogenous expression, use epitope-tagged N6AMT1 and detect using tag-specific antibodies.

• Parallel AURKA quantification: Simultaneously quantify AURKA to account for potential cross-reactivity .

• Multiple antibody validation: Use at least two antibodies targeting different epitopes and compare results.

• Careful control selection: Include appropriate positive and negative controls, including N6AMT1 knockdown/knockout samples.

• Normalization strategy: Implement robust normalization using stable reference proteins and consider using total protein normalization approaches.

• Calibrated protein standards: Use purified recombinant N6AMT1 protein as a standard for absolute quantification.